Last reviewed · How we verify
pegylated interferon alpha 2a and plus ribavirin
At a glance
| Generic name | pegylated interferon alpha 2a and plus ribavirin |
|---|---|
| Also known as | PEGASYS® |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (EARLY_PHASE1)
- Telaprevir in Genotype 3 HCV (PHASE4)
- A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures (PHASE1, PHASE2)
- High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV (PHASE3)
- Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (PHASE3)
- Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: